Probiotics in inflammatory bowel disease - Therapeutic rationale and role

Advanced Drug Delivery Reviews

Volumn 56, Issue 6, 2004, Pages 809-818

  Shanahan, Fergus ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

Crohn's disease; Inflammatory bowel disease; Probiotics; Ulcerative colitis

Indexed keywords

BACTERIA; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; IMMUNOLOGY; METABOLISM; NEUROLOGY;

NEUROMUSCULAR ACTIVITY; NUTRIENT PRODUCTION; PROBIOTICS; THERAPEUTIC STRATEGIES;

DISEASES;

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARCINOGEN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PROBIOTIC AGENT; PRODRUG; TUMOR NECROSIS FACTOR;

BACTERIUM; BIFIDOBACTERIUM; COMMENSALISM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; EPITHELIUM; EVIDENCE BASED MEDICINE; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; METABOLISM; MUCOSAL IMMUNITY; NONHUMAN; NUTRIENT; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY MECHANISM; RELIABILITY; REVIEW;

EID: 1942420154     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.11.003     Document Type: Article

References (70)

1. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology. 120:2001;622-635.
2. Shanahan F. Crohn's disease. Lancet. 359:2002;62-69.
3. Shanahan F. Crohn's disease. Sci. Med. 9:2003;48-58.
4. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut. 42:1998;2-7.
5. Shanahan F. Probiotics in inflammatory bowel disease: is there a scientific rationale? Inflamm. Bowel Dis. 6:2000;107-1115.
6. Berkelman R.L., Hughes J.M. The conquest of infectious diseases: who are we kidding? Ann. Int. Med. 119:1993;426-428.
7. Lorber B. Are all diseases infectious? Ann. Int. Med. 125:1996;844-851.
8. Tysk C., Lindberg E., Jarnerot G., Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut. 29:1988;990-996.
9. Ekbom A. The changing faces of Crohn's disease and ulcerative colitis. Targan S., Shanahan F., Karp L.C. Inflammatory Bowel Disease: From Bench to Bedside. 2nd ed. 2003;5-20 Kluwer Academic Publishers, Dordrecht.
10. Gent A.E., Hellier M.D., Grace R.H., Swarbrick E.T., Coggon G. Inflammatory bowel disease and domestic hygiene in infancy. Lancet. 343:1994;766-767.
11. Elliott D.E., Urban J.F. Jr., Argo C.K., Weinstock J.V. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB J. 14:2000;1848-1855.
12. Taylor K.D., Rotter J.I., Yang H. Genetics of inflammatory bowel disease. Targan S., Shanahan F., Karp L.C. Inflammatory Bowel Disease: From Bench to Bedside. 2nd ed. 2002;21-65 Kluwer Academic Publishers, Dordrecht.
13. Sartor R.B. Enteric microflora in IBD: pathogens or commensals? Inflamm. Bowel Dis. 3:1997;230-235.
14. Robertson D.J., Sandler R.S. Measles virus and Crohn's disease: a critical appraisal of the current literature. Inflamm. Bowel Dis. 7:2001;51-57.
15. Shanahan F. The host-microbe interface within the gut. Best Pract. Res. Clin. Gastroenterol. 16:2002;915-931.
16. McDonald T.T. The Hypothesized Link Between Dairy Products, Mybobacterium paratuberculosis and Crohn's Disease. 2001 (February);The Dairy Council (UK), London.
17. European Commission, Possible links between Crohn's disease and Paratuberculosis. Report of the Scientific Committee on Animal Health and Animal Welfare. (Adopted 21 March 2000). The European Commission.
18. Relman D.A. The search for unrecognised pathogens. Science. 284:1999;1308-1310.
19. Ryan P., Bennett M.W., Aarons S., Lee G., Collins J.K., O'Sullivan G.C., O'Connell J., Shanahan F. PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut. 51:2002;665-670.
20. Braun J. Unsettling facts of life: bacterial commensalism, epithelial adherence, and inflammatory bowel disease. Gastroenterology. 122:2002;228-230.
21. Keane J., Gershon F., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralising agent. New Engl. J. Med. 345:2001;1098-1104.
22. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:2001;675-680.
23. Bach J.-F. The effect of infections on susceptibility to autoimmune and allergic diseases. New Engl. J. Med. 347:2002;911-920.
24. Shanahan F. Mechanisms of immunologic sensation of intestinal contents. Am. J. Physiol. (Gastrointest. Liver Physiol.). 278:2000;G191-G196.
25. Rook G.A.W., Stanford J.L. Give us this day our daily germs. Immunol. Today. 19:1998;113-116.
26. Murch S.H. Toll of allergy reduced by probiotics. Lancet. 357:2001;1057-1059.
27. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:2001;599-603.
28. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., Cho J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 411:2001;603-606.
29. Midtvedt T. Microbial functional activities. Hanson L.A., Yolken R.H. Intestinal Microflora, Nestle Nutrition Workshop Series. vol. 42:1999;79-96 Lippincott-Raven, Philadelphia.
30. Gordon J.I., Hooper L.V., McNevin S.M., Wong M., Bry L. Epithelial cell growth and differentiation: III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Am. J. Physiol. (Gastrointest. Liver Physiol.). 273:1997;G565-G570.
31. Hooper L.V., Gordon J.I. Commensal host-bacterial relationships in the gut. Science. 292:2001;1115-1118.
32. Berg R.D. The indigenous gastrointestinal microflora. Trends Microbiol. 4:1996;430-435.
33. Bocci V. The neglected organ: bacterial flora has a crucial immunostimulatory role. Perspect. Biol. Med. 35:1992;251-260.
34. Vaughan E.E., Schut F., Heilig H.G.H.J., Zoetendal E.G., de Vos W.M., Akkermans A.D.L. A molecular view of the intestinal ecosystem. Curr. Issues Intest. Microbiol. 1:2000;1-12.
35. Akkermans A.D.L., Zoetendal E.G., Favier C.F., Heilig H.G.H.J., Akkermans-van Vliet W.M., de Vos W.M. Temperature and denaturing gradient gel electrophoresis analysis of 16S rRNA from human faecal samples. Biosci. Microflora. 19:2000;93-98.
36. Van de Merwe J.P., Stegeman J.H., Hazenberg M.P. The resident faecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease? Antonie van Leeuwenhoek. 49:1983;119-124.
37. FAO/WHO Expert Consultation, Report of a Joint FAO/WHO Expert Consultation. Health and Nutritional Properties of Probiotics in Food Including Powder Milk and Live Lactic Acid Bacteria, 2001, http://www.fao.org/es/ESN/ Probio/report.Pdf.
38. Working group report, Guidelines for the Evaluation of Probiotics in Food, Joint Food and Agriculture Organisation of the United Nations and The World Health Organisation, http://www.fao.org/es/ESN/Probio/probio.htm.
39. Shanahan F., McCarthy J. Functional foods and probiotics - time for gastroenterologists to embrace the concepts. Curr. Gastroenterol. Rep. 2:2000;345-346.
40. Shanahan F. Probiotics: a perspective on problems and pitfalls. Scand. J. Gastroenterol. 38:(Suppl. 237):2003;34-36.
41. Collins J.K., Dunne C., Murphy L., Morrissey D., O'Mahony L., O'Sullivan E., Fitzgerald G., Kiely B., O'Sullivan G.C., Daly C., Marteau P., Shanahan F. A randomised controlled trial of a probiotic Lactobacillus strain in healthy adults: assessment of its delivery, transit, and influence on microbial flora and enteric immunity. Microb. Ecol. Health Dis. 14:2002;81-89.
42. Dunne C., Shanahan F. Role of probiotics in the treatment of intestinal infections and inflammation. Curr. Opin. Gastroenterol. 18:2002;40-45.
43. Dugas B., Mercenier A., Lenoir-Wijnkoop I., Arnaud C., Dugas N., Postaire E. Immunity and probiotics. Immunol. Today. 20:1999;387-390.
44. Madsen K.L., Doyle J.S., Jewell L.D., Tavernini M.M., Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 116:1999;1107-1114.
45. O'Mahony L., Feeney M., O'Halloran S., Murphy L., Kiely B., Fitzgibbon J., Lee G., O'Sullivan G., Shanahan F., Collins J.K. Probiotic impact on microbial flora inflammation and tumor development in IL-10 knock out mice. Aliment. Pharmacol. Ther. 15:2001;1219-1225.
46. McCarthy J., O'Mahony L., O'Callaghan L., Shiel B., Vaughan E.E., Fitzsimons N., Fitzgibbon J., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 52:2003;975-980.
47. Bennet J.D., Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1:1989;164.
48. Prantera C., Scribano M.L., Falasco G., Andreoli A., Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 51:2002;405-409.
49. Guslandi M., Mezzi G., Sorghi M., Testoni P.A. Sacharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 45:2000;1462-1464.
50. Malchow H.A. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J. Clin. Gastroenterol. 25:1997;653-658.
51. Hamilton-Miller J.M.T. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect. Dis. Rev. 3:2001;83-87.
52. Kruis W., Schütz E., Fric P., Fixa B., Judmaiers G., Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11:1997;853-858.
53. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T.R. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 354:1999;635-639.
54. Gionchietti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., Poggioli G., Miglioli M., Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo-controlled trial. Gastroenterology. 119:2000;305-309.
55. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., Vitali B., Poggioli G., Miglioli M., Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 124:2003;1202-1209.
56. Flynn S., Van Sinderen D., Thornton G.M., Holo H., Nes I.F., Collins J.K. Characterisation of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. Salivarius UCC118. Microbiology. 148:2002;973-984.
57. Isolauri E., Majamaa H., Arvola T., Rantala I., Virtanen E., Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology. 105:1993;1643-1650.
58. Neish A.S., Gewirtz A.T., Zeng H., Young A.N., Hobert M.E., Karmali V., Rao A.S., Madara J.L. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination. Science. 289:2000;1560-1563.
59. Elewaut D., DiDonato J.A., Kim J.M., Truong F., Eckman L., Kagnoff M.F. NF-kB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J. Immunol. 163:1999;1457-1466.
60. ++-mediated activation of the NF-kB pathway. J. Clin. Invest. 105:2000;79-92.
61. Wagner H. Toll meets bacterial CpG-DNA. Immunity. 14:2001;499-502.
62. Wagner H. Bacterial CpG-DNA activates immune cells to signal infectious danger. Adv. Immunol. 73:1999;329-368.
63. Rachmilewitz D., Karmeli F., Takabayashi K., Hayashi T., Leider-Trejo L., Lee J., Leoni L.M., Raz E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 122:2002;1428-1441.
64. Steidler L., Hans L., Schotte W., Neirynck S., Obermeier F., Falk W., Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 289:2000;1352-1355.
65. Chang T.L.-Y., Chang C.-H., Simpson D.A., Xu Q., Martin P.K., Lagenaur L.A., Schoolnik G.K., Ho D.D., Hillier S.L., Holodniy M., Lewicki J.A., Lee P.P. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl. Acad. Sci. USA. 100:2003;11672-11677.
66. Shanahan F. Therapeutic manipulation of gut flora. Science. 289:2000;1311-1312.
67. Atlas R.M. Probiotics - snake oil for the new millennium? Environ. Microbiol. 1:1999;375-382.
68. Berg R.D. Probiotics, prebiotics or 'conbiotics'? Trends Microbiol. 6:1998;89-92.
69. Shanahan F. Probiotics: science or snakeoil? Clin. Perspect. Gastroenterol. 4:2001;47-50.
70. Konings W.N., Kok J., Kuipers O.P., Poolman B. Lactic acid bacteria: the bugs of the new millennium. Curr. Opin. Microbiol. 3:2000;276-282.